The new office will help develop a standardized approach to using personalized medicines, digital data and patient data. One of the main goals will be understanding how to turn what patients tell physicians into structured, actionable data.
The office will be part of the Office of New Drugs, which sits in the FDA’s Center for Drug Evaluation and Research, the overseer of new medication approval. It will have its own director, an 18-person division of clinical outcomes assessment team; an 18-person division of biomedical informatics and safety analytics; and an 11-person division of research and biomarker development.
FDA Commissioner Scott Gottlieb, MD, expects to set up the office in the first half of the year.
More articles on pharmacy:
Hospital-owned drug company attracts 12 more health systems
How nurses are becoming integral to pharma marketing: 7 notes
4 tips for managing drug spend from Alameda Health System’s Dr. Yi-Chih Peng
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.